MY146420A - Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors - Google Patents

Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Info

Publication number
MY146420A
MY146420A MYPI20091013A MYPI20091013A MY146420A MY 146420 A MY146420 A MY 146420A MY PI20091013 A MYPI20091013 A MY PI20091013A MY PI20091013 A MYPI20091013 A MY PI20091013A MY 146420 A MY146420 A MY 146420A
Authority
MY
Malaysia
Prior art keywords
inhibitors
pyrido
pyrimidinone compounds
compounds
pyrimidinone
Prior art date
Application number
MYPI20091013A
Other languages
English (en)
Inventor
Cheng Hengmio
Plewe Michael Bruno
Tran Khanh Tuan
Bhumralkar Dilip
Dress Klaus Ruprecht
Hoffman Jacqui Elizabeth
Johnson Mary Catherine
Kania Robert Steven
Le Phuong Thi Quy
Nambu Mitchell David
Pairish Mason Alan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY146420A publication Critical patent/MY146420A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
MYPI20091013A 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors MY146420A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
MY146420A true MY146420A (en) 2012-08-15

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20091013A MY146420A (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Country Status (41)

Country Link
US (3) US7696213B2 (enExample)
EP (1) EP2074122B9 (enExample)
JP (1) JP4718637B2 (enExample)
KR (1) KR101099926B1 (enExample)
CN (1) CN101573358B (enExample)
AP (1) AP2710A (enExample)
AR (1) AR062785A1 (enExample)
AT (1) ATE514695T1 (enExample)
AU (1) AU2007297212B8 (enExample)
BR (1) BRPI0716749B8 (enExample)
CA (1) CA2663401C (enExample)
CL (1) CL2007002682A1 (enExample)
CR (1) CR10662A (enExample)
CU (1) CU23783B7 (enExample)
CY (1) CY1111911T1 (enExample)
DK (1) DK2074122T5 (enExample)
DO (1) DOP2009000039A (enExample)
EA (1) EA016388B1 (enExample)
ES (1) ES2366489T3 (enExample)
GE (1) GEP20115306B (enExample)
GT (1) GT200700077A (enExample)
HN (1) HN2007000267A (enExample)
HR (1) HRP20110621T2 (enExample)
IL (1) IL197243A (enExample)
MA (1) MA30709B1 (enExample)
ME (1) MEP8009A (enExample)
MX (1) MX2009002927A (enExample)
MY (1) MY146420A (enExample)
NI (1) NI200900032A (enExample)
NO (1) NO342357B1 (enExample)
NZ (1) NZ575167A (enExample)
PE (1) PE20080670A1 (enExample)
PL (1) PL2074122T3 (enExample)
PT (1) PT2074122E (enExample)
RS (2) RS51927B (enExample)
SI (1) SI2074122T1 (enExample)
TN (1) TN2009000085A1 (enExample)
TW (1) TWI334353B (enExample)
UY (1) UY30588A1 (enExample)
WO (1) WO2008032162A1 (enExample)
ZA (1) ZA200901477B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE514695T1 (de) 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
CA2683641C (en) * 2007-04-10 2016-08-16 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
BRPI0810175A2 (pt) * 2007-04-11 2014-12-30 Exelixis Inc Inibidores pirididopirinidinona de p13k alfa
BRPI0915901A2 (pt) * 2008-07-11 2015-10-27 Novartis Ag combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2331511A1 (en) 2008-08-20 2011-06-15 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) * 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
PA8843901A1 (es) * 2008-09-30 2010-05-26 INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
DK2651951T3 (en) 2010-12-16 2014-12-08 Hoffmann La Roche TRICYCLIC PI3K INHIBITOR COMPOUNDS AND PROCEDURES FOR USE THEREOF
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
EP3549583A1 (en) 2014-10-10 2019-10-09 Pfizer Inc Synergistic auristatin combinations
HRP20192065T1 (hr) 2015-06-04 2020-02-21 Pfizer Inc. Čvrsti oblici doziranja palbocikliba
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンThe Regents Of The University Of Michigan MEK/PI3K及びmTOR/MEK/PI3K生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
JP2020503289A (ja) * 2016-12-14 2020-01-30 ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. Hsp90標的化コンジュゲート及びその製剤
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN117843659A (zh) 2018-06-15 2024-04-09 詹森药业有限公司 雷帕霉素类似物和其用途
AU2019413683B2 (en) * 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
CN114901664B (zh) * 2020-01-10 2024-07-02 南京再明医药有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
JP2024542205A (ja) * 2021-11-18 2024-11-13 オンコノヴァ セラピューティクス, インコーポレイテッド がんを処置するための方法および組成物
WO2024254511A2 (en) 2023-06-08 2024-12-12 Nimbus Wadjet, Inc. Wrn inhibitors
WO2025137599A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
AU1808601A (en) 2000-01-27 2001-08-07 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
DZ3308A1 (fr) 2000-03-06 2001-09-27 Warner Lambert Co Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
HRP20040660B1 (hr) 2002-01-22 2012-10-31 Warner-Lambert Company Llc 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
KR100816945B1 (ko) 2003-07-11 2008-03-25 워너-램버트 캄파니 엘엘씨 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DK1713806T3 (da) 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006021547A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 PI3Kα의 피리도피리미디논 억제제
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ATE514695T1 (de) * 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
AU2008224941C1 (en) * 2007-03-14 2013-06-27 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
BRPI0810175A2 (pt) * 2007-04-11 2014-12-30 Exelixis Inc Inibidores pirididopirinidinona de p13k alfa
PA8843901A1 (es) * 2008-09-30 2010-05-26 INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療

Also Published As

Publication number Publication date
AU2007297212A1 (en) 2008-03-20
WO2008032162A1 (en) 2008-03-20
ZA200901477B (en) 2010-07-28
GT200700077A (es) 2009-08-03
AU2007297212B8 (en) 2011-04-28
AR062785A1 (es) 2008-12-03
NI200900032A (es) 2010-05-14
US20080090801A1 (en) 2008-04-17
US20120309775A1 (en) 2012-12-06
TW200820972A (en) 2008-05-16
BRPI0716749B8 (pt) 2021-05-25
MX2009002927A (es) 2009-03-31
KR101099926B1 (ko) 2011-12-28
CN101573358A (zh) 2009-11-04
US20100137279A1 (en) 2010-06-03
DK2074122T3 (da) 2011-08-15
BRPI0716749B1 (pt) 2020-10-06
IL197243A0 (en) 2009-12-24
CR10662A (es) 2009-04-17
CU20090040A7 (es) 2011-07-11
ES2366489T3 (es) 2011-10-20
HK1138589A1 (en) 2010-08-27
US7696213B2 (en) 2010-04-13
EP2074122A1 (en) 2009-07-01
NZ575167A (en) 2010-10-29
PL2074122T3 (pl) 2011-10-31
RS20090104A (sr) 2010-06-30
AU2007297212B2 (en) 2011-04-14
NO342357B1 (no) 2018-05-14
HRP20110621T1 (hr) 2011-09-30
PE20080670A1 (es) 2008-06-14
BRPI0716749A2 (pt) 2014-02-18
CY1111911T1 (el) 2015-11-04
JP2010503653A (ja) 2010-02-04
EP2074122B1 (en) 2011-06-29
EA016388B1 (ru) 2012-04-30
MA30709B1 (fr) 2009-09-01
TN2009000085A1 (fr) 2010-08-19
IL197243A (en) 2013-07-31
MEP8009A (en) 2011-12-20
ES2366489T9 (es) 2013-12-27
CA2663401A1 (en) 2008-03-20
GEP20115306B (enExample) 2011-10-10
JP4718637B2 (ja) 2011-07-06
CN101573358B (zh) 2012-05-30
EA200970207A1 (ru) 2009-08-28
HN2007000267A (es) 2011-02-25
US8633204B2 (en) 2014-01-21
DK2074122T5 (da) 2014-03-17
WO2008032162A8 (en) 2009-03-26
SI2074122T1 (sl) 2011-10-28
KR20090040389A (ko) 2009-04-23
US8273755B2 (en) 2012-09-25
CA2663401C (en) 2011-07-12
UY30588A1 (es) 2008-05-02
AP2009004790A0 (en) 2009-04-30
ATE514695T1 (de) 2011-07-15
CL2007002682A1 (es) 2008-04-04
AP2710A (en) 2013-07-30
TWI334353B (en) 2010-12-11
NO20091141L (no) 2009-03-31
PT2074122E (pt) 2011-08-24
HRP20110621T2 (hr) 2013-12-06
DOP2009000039A (es) 2015-12-15
CU23783B7 (es) 2012-02-15
RS51927B (sr) 2012-02-29
EP2074122B9 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
EA201000113A1 (ru) Пиразольные соединения
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
WO2007105058A3 (en) Pyrazole compounds
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2007115931A8 (de) Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
UY31161A1 (es) Usos de derivados de cinolina en el tratamiento de la esquizofrenia
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
TW200628153A (en) Novel compounds
UA93609C2 (en) 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
ATE522530T1 (de) 2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
UY32895A (es) Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica